Stock Taper
Moderna, Inc. is a biotech company developing mRNA therapeutics and vaccines for infectious, autoimmune, and cancer diseases worldwide, with strategic partnerships and a diverse portfolio including COVID-19, flu, and personalized cancer vaccines.

Moderna's FDA-approved, lower-dose next-generation COVID-19 vaccine for the 2025-2026 season is its latest key product in the COVID-19 franchise.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Product Sales | $1.97B | $1.05B ▼ | $352M ▼ | $171M ▼ |
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $782M | $298M ▼ | $73M ▼ | $70M ▼ |
![]() | Europe | $16M | $37M ▲ | $239M ▲ | $16M ▼ |
![]() | Rest of the World | $175M | $347M ▲ | $40M ▼ | $8M ▼ |
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
RVMD | $203.78 | COMPARE |
JAZZ | $251.77 | COMPARE |
BBIO | $76.02 | COMPARE |
EXEL | $54.46 | COMPARE |
BMRN | $65.95 | COMPARE |
HALO | $106.37 | COMPARE |
MDGL | $529.53 | COMPARE |
TECH | $72.32 | COMPARE |